Dienst et al. later tested the anti-tumor activity of a recombinant fusion protein targeting tTF to both murine and human VCAM-1 antigens, using three human xenograft models (L540rec Hodgkin lymphoma; Colo677 small-cell lung carcinoma; and Colo677/HDMEC small-cell lung carcinoma with human vasculature) [26]. This evidence concerns the gene RHOH and neoplasm.